The prevalence of type 2 diabetes (T2D) around the world is undesirably increasing and undeniably creates a negative impact both on human health and the economy. Contributing factors such as insulin resistance, obesity, oxidative stress, and glucolipotoxicity condition expedite the development of T2D. As a major site for glucose disposal, skeletal muscle is a good target tissue for metabolic disorder therapy such as T2D. L-arginine (ARG), primarily contained in muscle-builder supplements, was investigated for its potential as an antiglycation, antioxidant, and antihyperlipidemic effect using some in vitro. Results indicated herein that L-arginine could dose-dependently exhibit an antiglycation effect (68.45 ± 1.32 %; 33.76 ± 1.34 %, respectively) using BSA-glucose and BSA-MGO models. Similarly, it was shown to protect 24.75 ± 0.78 % against potential protein damage using the Congo red binding assay. Antihyperlipidemic effects of L-arginine were also observed as it inhibited pancreatic lipase activity up to 39.62 ± 0.97 %, comparable to the positive control. Antioxidant and radical scavenging activities of L-arginine were also measured and found to inhibit 35.57 ± 1.65 %, 39.30 ± 2.36 %, 34.06 ± 0.21 %, and 93.57 ± 0.33 % formation reactive species using DPPH, FRAP, MDA, and Iron chelation assays, respectively. The preliminary results suggest that L-arginine might offer an alternative treatment strategy for type 2 diabetes.